No information available. |
Summary of Clinical Use |
Mosunetuzumab (BTCT4465A) was approved by both the EMA and FDA in 2022 [6]. It is indicated as a treatment for relapsed or refractory follicular lymphoma. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04712097 | A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy | Phase 3 Interventional | Hoffmann-La Roche | 3 | |
NCT02500407 | A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Phase 1/Phase 2 Interventional | Genentech, Inc. | 2 |